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BACKGROUND. Conversion into androgen-hypersensitive state and adaptation to the low
concentration of androgen during ADT cause relapse of prostate cancer (PCa). It is important
to identify differentially expressed genes between PCa and normal prostate tissues and to
reveal the function of these genes that are involved in progression of PCa.
METHODS. We performed cDNA microarray analysis to identify differentially expressed
genes, calcium/calmodulin-dependent protein kinase kinase 2 (CAMKK2). Immunohisto-
chemical analysis was conducted to investigate the relationship between the CAMKK2 ex-
pression level and prognosis. The function of CAMKK2 was assessed by generating
CAMKK2 overexpressed LNCaP cells and by knockdown of CAMKK2.
RESULTS. We identified CAMKK2 overexpressed six times in PCa more than normal pros-
tate by cDNA microarray analysis. Immunohistochemical analysis of CAMKK2 protein
showed that CAMKK2 protein was expressed more in PCa than normal tissue. However,
the expression in the high-grade PCa diminished. Moreover, the narrowness of CAMKK2-
positive area before ADT was a poor prognostic factor. Androgen-deprivation treatment
from the medium in which LNCaP cells were cultured in the presence of 10 nM DHT re-
pressed CAMKK2 expression. CAMKK2 overexpressed LNCaP cells (LNCaP/GFP-
CAMKK2) attenuated androgen-sensitivity. Tumorigenesis of LNCaP/GFP-CAMKK2
cells in male SCID mice was decreased compared with control cells irrespective of castration.
Finally, knockdown of CAMKK2 mRNA in LNCaP cells induced androgen-hypersensitivity
and stimulated LNCaP cell proliferation.
CONCLUSIONS. Induction of androgen-hypersensitivity after ADT may be involved in
down-regulation of CAMKK2. This result may provide new therapeutic approach to
keep androgen-sensitivity of PCa after ADT. Prostate 72: 1789–1801, 2012. # 2012 Wiley
Periodicals, Inc.
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Prostate cancer (PCa) is the most common malig-
nancy and the second leading cause of cancer-related
death of men in the United States [1]. Since advanced
PCa is initially dependent upon androgens, andro-
gen-deprivation therapy (ADT) is the first choice for
advanced PCa. Improvement of symptom or decrease
in prostate-specific antigen (PSA) is observed in
more than 90% of PCa patients by ADT. Unfortunate-
ly, after an initial response to ADT, PCa eventually
loses responsiveness to the androgen blockade and
progresses into castration-resistant prostate cancer
(CRPC).
Although multiple molecular mechanisms that
could explain the development to CRPC have
been proposed [2], androgen receptor (AR) is
still a key mediator in the progression of PCa [3].
Especially, an androgen-hypersensitive situation
of PCa plays an important role in an adaptation
to castrate levels of androgen that is secreted
from adrenal gland. Furthermore, intratumoral an-
drogen synthesis in PCa or bone metastasis region
also supplies androgen enough for androgen-
hypersensitive PCa cells to survive and proliferate
[4,5]. Moreover, not only cancer cells but also cancer-
associated fibroblasts coordinately synthesize dihy-
drotestosterone (DHT) from adrenal androgen
DHEA, activate AR, and enhanced the cell prolifera-
tion after ADT [5].
As for androgen-hypersensitivity, CRPC is induced
by several pathways: (A) promiscuous AR mutations.
AR with T877A and H874Y mutation responds to var-
ious ligands, such as DHEA, estradiol, and progester-
one [6,7]. (B) AR overexpression by AR gene
amplification [8], increase of AR promoter activity, or
AR mutation that increase AR stability [9]. (C) In-
crease of AR coactivators. Expression AR coactivator
ARA55 and TIFII was increased in some of CRPC
patients [10,11]. (D) Outlaw pathways through trans-
activation of kinases, or crosstalk with cytokines or
growth factor receptors [2]. AR coactivator p300 and
interleukin-6 coordinately activate AR and induce
PSA [12].
To identify biomarkers for PCa and key proteins
that induce carcinogenesis and progression during
ADT, gene expression profiling between normal pros-
tate and PCa was investigated using cDNA microar-
ray technique [13–16]. As a result, many molecules
have been identified as PCa markers, such as AMACR
(a-methylacyl coenzyme A racemase), as prognostic
biomarkers, such as MUC1 and AZGP1 [17], and as
the proteins that induce progression such as the poly-
comb gene EZH2 [18]. Holzbeierlein et al. [13] demon-
strated that overexpression of AR mRNA was also
observed in CRPC. Overexpression of the AR could
contribute to androgen-hypersensitivity in the low
concentration of androgen. Moreover, they also iden-
tified some of the genes that were differentially
expressed in resistant tumors and that could contrib-
ute to the process of reactivation.
In the present study, we also identified many
genes that were differentially expressed between
normal prostate and PCa tissue, and investigated
the functions of them. Then we focused on one of
overexpressed genes in PCa, calcium/calmodulin-
dependent protein kinase kinase 2 (CAMKK2). Re-
cently, Frigo et al. [19] and Massie et al. [19] reported
that CAMKK2 induced by androgen in PCa cells
stimulated migration, invasion, and cell growth.
However, we report that the size of CAMKK2-
positive area was inversely correlated with prognosis
and that down-regulation of CAMKK2 expression by




In order to identify the differentially expressed
genes between normal prostate and PCa tissue,
we compared expression profile between each of
three normal prostate biopsy samples and each
of three PCa samples using cDNA microarray analy-
sis. The characteristics of the patients were described
in Table I. cDNA microarray analysis was performed
in DNA Chip Research Inc. (Kanagawa, Japan) after
sending biopsy samples from the patients and ana-
lyzed by Whole Human Genome Microarray 4  44K
(Agilent Technologies; GEO accession number:
GSE30994). Needle biopsies were performed after we
obtained informed consent from patients with the
document approved from the Graduate School of
Medical Science, Kanazawa University.
Cell LinesandGenerationof StableTransformant
LNCaP and VCaP cells (ATCC, Manassas, VA)
were cultured in DMEM supplemented with 1%
penicillin/streptomycin (Invitrogen, Carlsbad, CA)
and 5% and 10% fetal bovine serum (Sigma–Aldrich,
St. Louis, MO), respectively. To generate CAMKK2-
overexpressed LNCaP cells, LNCaP cells were trans-
fected with 0.5 mg pCMV6-AC-GFP or pCMV6-
AC-GFP-CAMKK2 from OriGene Technologies
(Rockville, MD) using Lipofectamine reagent (Invitro-
gen). Eight hours after transfection, the cells were cul-
tured at 1,200 mg/ml G418 (Sigma–Aldrich) and





Twenty-four hours after cells were plated at a den-
sity of 5  104 cells onto 12-well plates with MDEM-
5% charcoal-stripped fetal calf serum (CCS; Thermo
Scientific HyClone, UK), cells were treated with or
without DHT in DMEM-5% CCS and the medium
was changed every 2 days. In each experiment, cells
were harvested and the numbers of the cells were
counted in triplicate using a hemocytometer. The data
represent the means  SD of three replicates.
RNAInterferenceAnalysis
The specific Stealth CAMKK2 and AR small inter-
fering RNAs (siRNAs) were synthesized by Invitro-
gen. CAMKK2 target siRNA-01 and -02 sequence
were 50-UUCGAACACCAUGUACAGAUGGUCC-30,
50-CAAUGAAGGACUCCAUGCCCAGG-UG-30, re-
spectively. Non-target (NT) siRNA were purchased
from Invitrogen. For CAMKK2 knockdown, LNCaP
cells were plated into 12-well plates at 5  104 cells/
well. After cultured for 24 hr, cells were transfected
with each density of 20 nM CAMKK2 siRNA or NT
siRNA using Lipofectamine RNAiMAX Reagent
(Invitrogen) for 24 hr. Total RNA or total proteins
were exacted after siRNA transfection. For cell prolif-
eration, after transfection of cells with NT siRNA or
CAMKK2 siRNA-01 for 12 hr, cells were treated with
0, 0.1, 1.0, and 10 nM DHT, and the numbers of the
cells were counted 4 days after transfection. Medium
was changed every 2 days and DHT was also added
to the medium.
RT-PCR
Total RNA extraction from cell cultures and RT-
PCR was performed followed as described previously
[5]. The sense and anti-sense primers used RT-PCR of
CAMKK2 are 50-CTGGACATGAACGGACGCTGCA-
TCT-30 and 50-GCCCTTGGTTGACCAGTTCGA-ACA
C-30, respectively. The annealing temperature of RT-
PCR of CAMKK2 was 658C and PCR cycle number
was 30 cycles. The amplified PCR products were visu-
alized using electrophoresis on a 1.5% agarose gel.
For quantification of mRNA expression, the gene ex-
pression in each sample was normalized by GAPDH
gene expression.
LuciferaseAssay
To evaluate AR transcriptional activity, 24 hr after
plating 5  104 cells on 12-well plates in DMEM-5%
CCS, LNCaP and its sublimes were transfected using
Lipofectamine transfection reaction (Invitrogen) using
0.5 mg of luciferase reporter plasmid, pGLPSAp-5.8,
driven by a 5.8 kb PSA promoter including 3 andro-
gen-response elements (ARE) [21]. Twelve hours after
transfection, cells were treated by the addition of indi-
cated concentration of DHT for 24 hr. After treated
cells were harvested, cells were lysed in luciferasely-
sis buffer (Promega, WI). As for knockdown
CAMKK2 expression in LNCaP cells, 5  104 LNCaP
cells were transfected with 20 nM NT siRNA or
CAMKK2 siRNA (Invitrogen) using RNAiMAX (Invi-
trogen) for 12 hr and then LNCaP cells were further
transfected with pGL3PSAp-5.8 for 12 hr. After
changing medium, transfected LNCaP cells were cul-
tured for 24 hr and harvested.
WesternBlotAnalysis
After finishing various treatments, total protein was
extracted from cells as described previously [22].
Protein was quantified according to the method of
Bradford, and equal amounts of protein were electro-
phoresed on a 10% or 12.5% Ready Gel J (Bio-Rad,
Hercules, CA). Membranes were incubated with mouse
monoclonal antibody against CAMKK2 (Sigma–
Aldrich), GAPDH (Novus Biologicals, Littleton, CO),
AR (NH27) [23]. Horseradish peroxidase-conjugated
secondary antibody against anti-mouse monoclonal or
anti-rabbit monoclonal antibody was used and protein
bands were visualized and quantitated with chemilu-
minescent reagent (SuperSignal West Pico Chemilumi-
nescent Substrate; Pierce, Rockford, IL) and ChemiDoc
XRS (Bio-Rad)
Animal Study
Severe combined immunodeficient (SCID) mice
were castrated 1 week before implantation of
LNCaP/GFP and LNCaP/GFP-CAMKK2 cells. The
cells were combined with 50% Matrigel (Collaborative
Biomedical Products, Bedford, MA) and 2  106 cells
were prepared for injection into the dorsal subcutis of
6-week-old male SCID mice castrated 1 week ago and




(ng/ml) Gleason score Stage
P01 59 3.6 BPH (33 g)
P02 74 8.97 BPH (67 g)
P03 70 5.09 BPH (50 g)
P11 77 55 4 þ 4 ¼ 8 T3a, N0, M0
P12 72 227.8 4 þ 4 ¼ 8 T4, N1, M0
P13 82 96.7 4 þ 3 ¼ 7 T3a, N0, M0
BPH, benign prostate hypertrophy.
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dorsal tumor volume and body weights were moni-
tored. Tumor growth was assessed by electronic
caliper measurement of tumor diameter in two
dimensions, and the tumor volume (V) was calculated
from the length (L) and width (W) according to the
formula V ¼ LW2/2. Serum from mice was taken for
enzyme immunoassay of prostate-specific antigen
(PSA) just before sacrifice and was frozen until mea-
surement. To measure the concentration of PSA in se-
rum of SCID mice, we asked SRL (Special Reference
Laboratories, Inc. Japan). This animal protocol was
approved by the Institutional Animal Care and Use
Committee of the Graduate School of Medical Science,
Kanazawa University.
ImmunohistochemistryofCAMKK2
TM0016 tissue microarrays (TMAs) comprised of
80 cores containing normal tissue, matched for Glea-
son score at Sutgery were purchased from Provitro
(Berlin, Germany) and PR952 TMAs comprised of 95
cores were purchased from Biomax (Rockville, MD).
The procedure for immunohistochemical staining
(IHC) was performed using a Dako ChemMate
ENVISION Kit/HRP(DAB)-universal kit (K5007)
according to the manufacturer’s protocol (Dako,
Carpinteria, CA). Tissue specimens were stained with
mouse monoclonal antibodies against CAMKK2 (a di-
lution of 1:200; Sigma–Aldrich). Japanese patient’s
prostate tissues were obtained from needle biopsy
of prostate on diagnosis in Kanazawa University
Hospital. We picked up advanced PCa patients with
bone metastasis. We obtained informed consent of
patients for research and were admitted our research
in the Institutional Review Board of the Graduate
School of Medical Science, Kanazawa University.
The procedure for IHC staining was the same of tis-
sue microarray except dilution of the primary anti-
body at 1:400.
ImmunofluorescenceStaining
Methods of immunofluorescence staining was fol-
lowed by previous study [24]. Briefly, staining for
CAMKK2 protein was performed by overnight incu-
bation using commercial kits in accordance with
the manufacturer’s instructions (Phallotoxins and
ZenonTM Tricolor Mouse and Rabbit IgG Labeling
Kit; Molecular Probes, Eugene, OR). We compared
the rate of a regional area with positive CAMKK2 ex-
pression with PSA-progression-free survival (PFS).
StatisticalAnalysis
Statistical significance was determined by using
the Prism 4.0 software. The chi-square test was
utilized to assess the significance between different
proportions. Analysis of continuous variables be-
tween different groups was assessed by one-way
analysis of variance followed by Fisher’s protected
least significant difference test. , , and  repre-
sent significant difference P < 0.05, P < 0.01, and
P < 0.001, respectively. Kruskal–Wallis test was used
to determine the statistical significance of differences
in IHC staining of tissue microarray. Logistic regres-
sion analysis was used to determine correlation of




To identify differentially expressed genes between
normal prostate and PCa tissue, approximately 40,000
genes were screened by cDNA microarray analysis
using mRNA from six different prostate biopsy sam-
ples from as described in Materials and Methods sec-
tion (Table I). Seventy-nine (0.2%) of screened genes
were up-regulated (2.5-fold) and 124 (0.31%) of
genes were down-regulated in each of three PCa sam-
ples (0.25-fold) compared with each of three normal
prostate samples. Then we focused on CAMKK2 (cal-
cium/calmodulin-dependent protein kinase kinase 2)
which was a relatively highly expressed and >6-fold
up-regulated in three PCa tissues compared with
three normal prostate tissues.
First, we investigated if the CAMKK2 expression
pattern on cDNA microarray is correlated with clini-
cal PCa samples. As shown in Figure 1A–C, we classi-
fied intensity of the CAMKK2 staining of cytoplasm
in three phases. Immunohistochemistry (IHC) of
CAMKK2 using tissue microarray revealed that 87.8%
(115/131) cases of primary PCa tissue and 85.7% (6/
7) cases of bone metastasis showed positive staining
in cytoplasm, whereas only 4.2% (1/24) of normal
prostate showed positive staining (P < 0.01; Fig. 1D).
Interestingly, the ratio of CAMKK2-negative staining
rather diminished in the PCa tissue with the high
Gleason score 8, 9, and 10 significantly compared
with low Gleason score (P ¼ 0.014). Therefore, we
also investigated the correlation between CAMKK2
expression and prognosis (progression-free survival,
PFS) of Japanese advanced PCa patients treated with
first-line androgen-deprivation therapy (ADT). All
patients had a diagnosis of the advanced PCa with
bone metastases. Since PCa is multifocal disease and
the transected tissue area can vary significantly in
composition of cell type, we evaluated biopsy sam-
ples at the area of CAMKK2-positive cells. As shown
in Figure 1E, regardless of an intensity of the expres-
sion of CAMKK2, the patients with area that
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CAMKK2 expression positive cells occupied <50%
had a poorer PFS significantly than the patients
with the area that CAMKK2 expression positive cells
occupied was bigger than 50% (median PFS 6 vs.
19 months, respectively; P ¼ 0.0031).
Androgen InducesCAMKK2Expression
Since PCa is generally androgen-dependent before
ADT, we confirmed if dihydrotestosterone (DHT)
can induce CAMKK2 in LNCaP cells. DHT-induced
CAMKK2 mRNA in a dose-dependent manner in
24 hr (Fig. 2A). Western blot analysis also revealed
that DHT-induced 72 kDa CAMKK2 protein expres-
sion in a dose-dependent manner. In contrast, andro-
gen-deprivation treatment from the medium in which
LNCaP cells were cultured in the presence of 10 nM
DHT gradually repressed CAMKK2 mRNA and pro-
tein expression (Fig. 2B).
OverexpressionofCAMKK2 inLNCaPCells
RepressesCell Proliferation
To explore the function of CAMKK2 on PCa cells,
we first generated stably CAMKK2 overexpressed
LNCaP cells (LNCaP/GFP-CAMKK2). Ninety-nine
kDa GFP-fused CAMKK2 protein was dominantly
expressed in cytoplasm of LNCaP/GFP-CAMKK2
cells (Fig. 2B and C). DHT of various concentrations
did not change AR mRNA expression in both
LNCaP/GFP and LNCaP/GFP-CAMKK2 cells. In
contrast, AR protein level in LNCaP/GFP-CAMKK2
cells was lower than that in LNCaP/GFP cells irre-
spective of DHT (Fig. 2D).
Fig. 1. ImmunohistochemistryofCAMKK2 inprostate tissue.Representative examples of photomicrographs (100  magnification) show-
ingCAMKK2expressionin thenormalprostateandprostatecancerontissuemicroarrayanalysis.A:CAMKK2expressioninnormalprostate
tissue (intensity).B: CAMKK2expression inprostate cancerwithGleason score 8 (intensityþ).C: CAMKK2expression inprostate cancer
with Gleason score 7 (intensityþþ).D: Immunohistochemistry of CAMKK2 on prostate tissue microarray. E: Kaplan^Meier estimates of
PSA-progression free survival for the indicated CAMKK2-positive area. The patients were classified in two groups by the rate of the




Fig. 2. InductionofCAMKK2byandrogenandgenerationof stable transformantofCAMKK2 inLNCaPcells.A:LNCaPcellswere treated
with DHT (0, 0.1, 1.0, and 10 nM) for 24 hr and total RNAs were extracted and subjected to real-time RT-PCR of CAMKK2 and GAPDH.
Whole cell lysate from each sample was also subjected toWestern blot analysis. Anti-CAMKK2 antibody and anti-GAPDH antibody were
used for detection of 72 kDa CAMKK2 and 37 kDa GAPDH protein, respectively. B: Twenty-four hours after seeding of LNCaP cells,
cells were treatedwith10 nMDHT for12 hr.Then themediumwas changed to DMEM-5% CCS to remove DHTand the cells were cultured
for12, 24, and 36 hr and harvested.The expression level of CAMKK2 mRNA and protein was subjected to real-time RT-PCR andWestern
blot analysis. C: Generation of stable transformant of GFP or GFP-CAMKK2 in LNCaP cells. Total RNA and whole cell lysate from
LNCaP/GFP and LNCaP/GFP-CAMKK2 were subjected to RT-PCR and Western blot analysis, respectively. D: Immunofluorescence
analysis of CAMKK2 in LNCaP/GFP and LNCaP/GFP-CAMKK2. Immunofluorescence analysis were performed usingmouse anti-CAMKK2
antibody (red) as described in theMaterials andMethods Section, and theblue signal represents nuclearDNA staining (400magnification).
E: After cells were treated with 0, 0.1, 1.0, and 10 nM DHT for 24 hr, total RNAs were extracted and subjected to RT-PCR of AR and
GAPDH.Whole cell lysatesweresubjectedtoWesternblotanalysisof110 kDaARandGAPDH48 hr after10 nMDHT-treatment.
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We further performed luciferase reporter assay to
confirm how CAMKK2 overexpression affect AR
activity in LNCaP cells. LNCaP/GFP and LNCaP/
GFP-CAMKK2 cells were transfected with a luciferase
reporter (pGL3PSAp-5.8) driven by 5.8 kbp PSA pro-
moter that includes strong 4.1 kbp upstream andro-
gen-response element (ARE3) and weak ARE1 and 2
[25]. The PSA promoter activity induced by DHT in
LNCaP/GFP-CAMKK2 cells was two to four times
lower than in LNCaP/GFP cells (Fig. 3A). Moreover,
basal level of PSA promoter activity in the absence of
DHT was also reduced in LNCaP/GFP-CAMKK2
cells by 2.7-fold compared with LNCaP/GFP cells.
Since CAMKK2 overexpression down-regulated
PSA promoter activity in the presence and absence of
DHT, we also explored the effect of CAMKK2 over-
expression on LNCaP cell proliferation. The prolifera-
tion rate of LNCaP/GFP-CAMKK2 cells without
DHT was diminished compared with LNCaP/GFP
cells (P < 0.05; Fig. 3B). Moreover, whereas the
Fig. 3. Effect of CAMK2 overexpression on LNCaP cells. A: After transfection of LNCaP/GFP and LNCaP/GFP-CAMKK2 cells with
pGL3PSAp-5.8, cellswere treatedwith 0,0.1, or1.0 nMDHT for 24 hr andluciferaseactivity was examined.B: AfterLNCaP/GFP andLNCaP/
GFP-CAMKK2 cells were treated with 0, 0.1, 1.0, and 10 nMDHT for 4 days, the numbers of LNCaP/GFP and LNCaP/GFP-CAMKK2 cells
were counted. C: After 2  106 LNCaP/GFP, LNCaP/GFP-CAMKK2 cells were injected into dorsal subcutis of intact SCID mice, the
volume of dorsal tumor was monitored every 3 or 4 days. All values are expressed as mean  SE.D: Enzyme immunoassay of PSAwas
performed in serum of SCIDmice that were sacrificed.E: After 2  106 LNCaP/GFP, LNCaP/GFP-CAMKK2 cells were injected into dorsal
subcutisofcastratedSCIDmice, thevolumeofdorsal tumorwasmonitored.F:EnzymeimmunoassayofPSAwasalsoperformedas (D).
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proliferation of LNCaP/GFP cells was stimulated
in 0.1 nM DHT most, the proliferation of LNCaP/
GFP-CAMKK2 cells was stimulated in 1 nM DHT
most (P < 0.001; Fig. 3B). This result suggested that
the androgen-sensitivity of LNCaP cells was dimin-
ished by CAMKK2 overexpression.
To assess the effect of CAMKK2 overexpression on
tumorigenesis in xenograft model, LNCaP/GFP and
LNCaP/GFP-CAMKK2 cells were injected subcutane-
ously in dorsal flank of intact male SCID mice. The
growth rate of LNCaP/GFP-CAMKK2 cells was sig-
nificantly declined to 25% of LNCaP/GFP cells at
day 115 (P ¼ 0.017; Fig. 3C). In accordance with
growth, mean serum PSA value on sacrifice in
LNCaP/GFP-CAMKK2-bearing mice was decreased
by 4.2-fold compared with LNCaP/GFP-bearing mice
(P < 0.01; Fig. 3D). We simultaneously assessed
the tumorigenesis of LNCaP/GFP-CAMKK2 cells
in male SCID mice castrated 1 week ago. Eventually,
the growth rate of LNCaP/GFP and LNCaP/GFP-
CAMKK2 cells was decrease in castrated mice com-
pared with intact mice (compare Fig. 3C and E). Then
the growth rate of LNCaP/GFP-CAMKK2 cells was
declined to 15% of LNCaP/GFP cells in castrated
mice at day 130 (P < 0.05; Fig. 3E). Serum PSA value
on sacrifice in LNCaP/GFP-CAMKK2-bearing mice
also decreased by 8.8-fold compared with LNCaP/
GFP-bearing mice (P < 0.05; Fig. 3F). These results
suggested that CAMKK2 overexpression in LNCaP
cells inhibit cell proliferation in vitro and in vivo irre-
spective of androgen.
KnockdownofCAMKK2 InducesARActivity
Since significant overexpression of a certain protein
using a strong artificial promoter, such as CMV pro-
moter, might cause a stress on the cell and thus de-
crease its growth rates. We, therefore, reduced
CAMKK2 expression using small interfering RNA
conversely. Two different siRNA (siCAMKK2-01 and
02) were first employed for knockdown of CAMKK2.
Knockdown of CAMKK2 by siCAMKK2-01 and 02 re-
pressed CAMKK2 mRNA expression and CAMKK2
protein expression by order of CAMKK2-01 and 02
(Fig. 4A). We evaluated the effect of knockdown of
CAMKK2 on PSA promoter activity in LNCaP cells
by luciferase reporter assay. In accordance with
knockdown of CAMKK2, PSA promoter activity was
inversely correlated with CAMKK2 protein expres-
sion (Fig. 4B). Especially, knockdown of CAMKK2 by
20 nM siCAMKK2-01 enhanced 3.6 times PSA pro-
moter activity induced by 0.1 nM DHT compared
with control non-target siRNA (siNT). Therefore, we
chose siCAMKK2-01 for further knockdown study of
CAMKK2. Knockdown of CAMKK2 by siCAMKK2
enhanced PSA promoter activity induced by 0.1 nM
DHT from 1.9 to 4.1 times compared with siNT in a
dose-dependent manner (Fig. 4C). We further investi-
gated if knockdown of CAMKK2 expression affect
different androgen-inducible MMTV promoter activi-
ty. MMTV promoter induced by 1.0 nM DHT as
well as PSA promoter was enhanced by knockdown
of CAMKK2 (Fig. 4D). In accordance with induction
of PSA promoter activity by knockdown of CAMKK2,
LNCaP cell proliferation was stimulated by knock-
down of CAMKK2 (Fig. 4E). Especially, proliferation
stimulation by the addition of 0.1 nM DHT was
further enhanced by knockdown of CAMKK2, sug-
gesting that androgen-sensitivity was enhanced by
down-regulation of CAMKK2 expression.
In order to confirm whether a phenomenon ob-
served with LNCaP cells applied to other cells, we
used androgen-sensitive PCa VCaP cells and per-
formed a similar experiment. DHT-induced PSA and
MMTV promoter activity in VCaP cells was enhanced
by knockdown of CAMKK2, suggesting that this phe-
nomenon is common events observed in androgen-
sensitive cells (Fig. 4F).
Since overexpression of CAMKK2-reduced AR
protein level in the presence of DHT as described
above, we explored AR expression level on knock-
down of CAMKK2 by siCAMKK2. As we expected,
AR expression level that was increased 24 hr after
DHT-treatment was further elevated by knockdown
of CAMKK2, although it was not changed in the ab-
sence of DHT by knockdown of CAMKK2 (Fig. 5A).
To further confirm if basal PSA promoter activity in-
duced by knockdown of CAMKK2 is related with
AR activity, we employed another reporter vector
driven by a 633 bp deleted PSA promoter that
includes only two weak AREs (pGL3PSAp-0.63) for
this experiment. As compared with pGL3PSAp-5.8
that includes strong ARE3, LNCaP cells transfected
with pGL3PSAp-0.63 showed weak induction of PSA
promoter activity by DHT (two times). Interestingly,
not only basal PSA promoter activity but also DHT-
induced PSA promoter activity of pGL3PSAp-0.63
was not enhanced by knockdown of CAMKK2
(Fig. 5B). These results suggested that enhancement of
AR promoter activity by knockdown of CAMKK2
might be mediated by not only AR stability but also
other transcriptional factors related with ARE3.
DISCUSSION
In the present study, we demonstrated that
CAMKK2 identified by cDNA microarray technique
had a function as a putative tumor suppressor and




Eventually CAMKK2 protein was expressed more
in PCa tissue samples than in normal prostate
tissue in accordance with cDNA microarray analysis
between normal prostate and PCa samples,
suggesting that CAMMKK2 can become the useful
immunohistochemical biomarker of PCa. However,
the CAMKK2-negative staining in tissue microarray
samples was rather increased in PCa patients
Fig. 4. Effect of knockdown of CAMKK2 expression on AR activity.A: Knockdown of CAMKK2 expression in LNCaP cells by CAMKK2
siRNA-01and -02 transfection.Twenty-four hours or 72 hr after transfectionwith NTsiRNA or CAMKK2 siRNA-01or -02, total RNA or
total proteins from LNCaP cells were extracted and subjected to RT-PCR or Western blot analysis of CAMKK2 and GAPDH, respectively.
B: Enhancementof PSApromoter activitybyknockdownofCAMKK2.PSApromoter activity inducedbyDHTwas examined after transfec-
tion with NTsiRNA or CAMKK2 siRNA-01 and -02.C: After LNCaP cells were transfected with 5,10, or 20 nMNTsiRNA or CAMKK2
siRNA for12 hr, cells were transfected with pGL3PSAp-5.8.D: After LNCaP cells were transfected with NTsiRNA or CAMKK2 siRNA,
cells were transfectedwith pGL3PSAp-5.8 (PSA promoter) or pGL3MMTV (MMTV promoter andwere treatedwith 0.1 nMDHTor1.0 nM




with high Gleason score. Moreover, when an expres-
sion of CAMKK2-positive area was narrow in PCa tis-
sue, PSA-progression free survival rate after first
ADT was low. The phenomenon that CAMKK2 is
expressed in PCa more than in normal prostate may
be contribution to the carcinogenesis of PCa. Howev-
er, once PCa is formed to some size, a function of
CAMKK2 may changes and CAMKK2 may act to
make a cell proliferation inhibited. In contrast,
among the various cells and organs, homeostasis is
often preserved by the feedback function through var-
ious hormones and cytokines. Even if it is PCa cells,
expression of CAMKK2 that is promoted by androgen
may regulate a rapid cell proliferation by negative
feedback, so called forming a negative regulatory
loop to maintain a balance in proliferation between
androgen and CAMKK2. It is well-known phenome-
non that the proliferation of LNCaP cells shows bi-
phasic pattern on androgen concentration: DHT of
the high concentration rather inhibited the LNCaP
proliferation [26] (Figs. 3B and 4E). Nevertheless,
CAMKK2 expression was induced by DHT in a dose-
dependent manner (Fig. 2A). Furthermore, overex-
pression of CAMKK2 repressed the proliferation of
LNCaP cells and attenuated androgen-sensitivity,
and that down-regulation of CAMKK2 stimulated cell
proliferation and enhanced androgen-sensitivity for
DHT of the low concentration. Thus, low expression
of CAMKK2 as a tumor suppressor before ADT or
down-regulation of CAMKK2 by ADT may contribute
relapse of PCa in response to adrenal androgen of the
low concentration at later stage. This similar phenom-
enon is also observed in suppressors of cytokine
signaling (SOCS)-3. SOCS-3 as well as CAMKK2 are
up-regulated by androgen in PCa cell lines and inhibit
androgen-mediated proliferation [27].
How does CAMKK2 expression repress AR-signal-
ing axis and proliferation? One of its mechanisms
may be involvement of AR protein. Overexpression of
CAMKK2 repressed AR protein level (Fig. 2). Pelley
et al. described that Ca2þ stimulated AR breakdown
in vitro and in vivo and that calmodulin bound to AR
seemed to play a role in calpain-mediated cleavage
of AR in LNCaP cells [28,29]. Together, the effect of
CAMKK2 on AR protein stability in the presence of
androgen may change AR-signaling axis.
The other reason for influence of CAMKK2 on cell
proliferation may be the activation of AMPK by
AMPK phosphorylation. CAMKK2 is upstream pro-
tein kinase for AMPK [30]. Zhou et al. demonstrated
that inactivation of AMPK by dominant negative
AMPK mutant accelerated cell proliferation and pro-
moted malignant behavior such as increased
cell migration and anchorage-independent prolifera-
tion mediating through lipopolysaccharide-induced
tumor necrosis factor (TNF) alpha factor (LITAF) and
TNF superfamily member 15 (TNFSF15) [31,32].
Serine-threonine liver kinase B1 (LKB1) known as a
tumor suppressor also activates AMPK, and have cru-
cial roles in cell proliferation [33]. One of the major
Fig. 5. EffectofknockdownofCAMKK2onARactivityinLNCaPcells.A:AfterLNCaPcellswere transfectedwithNTsiRNAorCAMKK2
siRNA, cellswere treatedwith 0 or10 nMDHT for 24 hr andwhole cell lysateswere extracted forWesternblot analysis ofAR andGAPDH.
B: LNCaP cells were transfected with NT siRNA or CAMKK2 siRNA. Then LNCaP cells were transfected with pGL3PSAp-0.63 or
pGL3PSAp-5.8andtreatedwith0or1 nMDHTfor24 hr, andluciferaseassaywasperformed.
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proliferation regulatory pathways controlled by
LKB1–AMPK is the mTOR (mammalian Target of
Rapamycin) pathway. The mTOR pathway is inhib-
ited through tuberous sclerosis complex 2 (TSC2)
known as a tumor suppressor [33]. Activation of
AMPK by CAMKK2 overexpression might repress
PCa proliferation through mTOR inhibition as well
as LKB1. Park et al. [34] demonstrated that AMPK
was highly activated in 40% of human PCa and act as
a metabolic survival factor. In breast cancer, reduced
phsphorylated AMPK signal was significantly associ-
ated with higher histological grade and axillary node
metastasis [35]. These reports suggest that the regula-
tion of CAMKK2 on cell proliferation in PCa is medi-
ated through AMPK activation.
However, the function of CAMKK2-AMPK path-
way is still controversial [19,20]. Frigo et al. [19] and
Massie et al. [20] demonstrated that CAMKK2-
induced migration and invasion of LNCaP cells and
stimulated LNCaP cell growth mediating through
phosphorylation of AMPK. IHC in our study revealed
that the ratio of CAMKK2-negative staining in the
PCa with the high-grade Gleason score that has
more malignant potential was increased compared
with the low-grade Gleason score. Furthermore, our
present study that CAMKK2-AMPK pathway inhib-
ited PCa growth is rather coincident with Zhou et al.
[31] and Hadad et al. [35]. It remains unclear why
CAMKK2-AMPK pathway show different functions.
The function of CAMKK2 may change at different sit-
uation, such as late stage of CRPC. Further study will
be needed to clarify this pathway.
As described in Figure 6, these observations raise
the intriguing mechanism that hormone-naive PCa
that initially responds to ADT becomes castration-
resistant. Before hormonal therapy, CAMKK2 is
expressing in response to androgen. It may be the
cause why a proliferation rate of the PCa is generally
slow compared with other cancers, such as lung
cancer and colon cancer that expression of
CAMKK2 controls excessive growth of PCa through
activation of AMPK or other signals. However, when
ADT is conducted for PCa, expression of CAMKK2 in
the PCa attenuates, and activation of AMPK is re-
pressed. As a result, PCa changes in the state that is
androgen-hypersensitive, and androgen of the low
Fig. 6. FunctionofCAMKK2onPCa.Therole ofCAMKK2onPCagrowthandamechanismof transition toCRPCduringADT.
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concentration promotes growth of the PCa and shifts
in CRPC.
Atorvastatin known as a statin famous for the con-
trol of hypercholesterolemia also activates CaMKK2
as an upstream kinase of AMPK in endothelium [36].
Recently, Zheng et al. demonstrated that administra-
tion of a combination of atorvastatin and celecoxib
might be an effective strategy for the prevention of
PCa LNCaP cell progression from androgen depen-
dence to androgen independence in castrated SCID
mice [37]. Although down-regulation of CAMKK2
assists recurrence as described above, the continuous
activation of CAMKK2 with some reagents such as
atorvastatin may prevent recurrence during ADT.
In conclusion, we suggest that ADT down-
regulates CAMKK2 and that CAMKK2 subsequently
stabilize AR that is a key mediator of hormonal sig-
naling. Moreover, the finding that CAMKK2 expres-
sion is reduced in more malignant PCa suggests that
loss of CAMKK2 may enhance androgen signaling
and promote prostate cell proliferation. Furthermore,
the fact that overexpression of CAMKK2 in vivo
reduces tumor growth suggests that reactivation of
CAMKK2 by development of new drugs may be a
new strategy to prolong the period to respond ADT
and inhibit PCa progression.
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